| a short report on highlights of worldwide development of rix4414: a singaporean experience. | in singapore, we conducted a phase ii randomized, double-blind, placebo-controlled dose ranging study using an attenuated human rotavirus vaccine, rix4414. altogether, 2464 healthy infants were recruited. two oral doses of vaccine at 104.7, 105.2 or 106.1 ffu or placebo were administered with routine immunizations at 3 and 4 months of age. seroconversion and 'vaccine take' in the vaccine groups 1-month post dose 2 varied from 76 to 91% and 98 to 100% respectively. vaccine was well tolerated and ... | 2006 | 16600443 |
| efficacy, immunogenicity and safety of a human rotavirus vaccine rix4414 in singaporean infants. | this was the first study conducted to evaluate the efficacy of 2 oral doses of the human rotavirus vaccine, rix4414 in singaporean infants during the first 3 years of life. | 2016 | 27125345 |
| intussusception and monovalent rotavirus vaccination in singapore: self-controlled case series and risk-benefit study. | to investigate the association between monovalent human rotavirus vaccine (rv1) and intussusception among asian infants and the impact of older age of vaccination. to perform risk-benefit analysis of rv1 vaccination programs in singapore. | 2015 | 25882872 |